{
    "ticker": "INM",
    "name": "InMed Pharmaceuticals Inc.",
    "description": "InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. Founded in 2010, InMed is dedicated to leveraging the therapeutic potential of cannabinoids through innovative drug development. The company's proprietary drug development platform, which combines cannabinoid biosynthesis and formulation expertise, allows it to create novel cannabinoid-based therapies tailored for specific medical conditions. InMed is advancing its lead product candidate, INM-088, for the treatment of ocular diseases, specifically targeting glaucoma. The company is also exploring other indications such as rare metabolic disorders and neurodegenerative diseases, harnessing the natural properties of cannabinoids to promote healing and improve patient outcomes. With a strong commitment to scientific research and development, InMed aims to pioneer new treatment avenues in the rapidly evolving cannabis pharmaceutical landscape. The company\u2019s mission is to unlock the therapeutic benefits of cannabinoids while ensuring safety and efficacy through rigorous clinical trials and regulatory compliance.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "2010",
    "website": "https://www.inmedpharma.com",
    "ceo": "Eric A. Adams",
    "social_media": {
        "twitter": "https://twitter.com/inmedpharma",
        "linkedin": "https://www.linkedin.com/company/inmed-pharmaceuticals/"
    },
    "investor_relations": "https://www.inmedpharma.com/investors",
    "key_executives": [
        {
            "name": "Eric A. Adams",
            "position": "CEO"
        },
        {
            "name": "Sabrina D. M. S. S. M. S.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "INM-088"
            ]
        }
    ],
    "seo": {
        "meta_title": "InMed Pharmaceuticals Inc. | Innovating Cannabinoid-Based Therapies",
        "meta_description": "Explore InMed Pharmaceuticals Inc., a leader in cannabinoid-based drug development. Learn about our innovative therapies and commitment to addressing unmet medical needs.",
        "keywords": [
            "InMed Pharmaceuticals",
            "Cannabinoid Therapies",
            "Pharmaceuticals",
            "Biotechnology",
            "INM-088"
        ]
    },
    "faq": [
        {
            "question": "What is InMed Pharmaceuticals known for?",
            "answer": "InMed Pharmaceuticals is known for developing cannabinoid-based therapies for various medical conditions."
        },
        {
            "question": "Who is the CEO of InMed Pharmaceuticals?",
            "answer": "Eric A. Adams is the CEO of InMed Pharmaceuticals Inc."
        },
        {
            "question": "Where is InMed Pharmaceuticals headquartered?",
            "answer": "InMed Pharmaceuticals is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What is InMed's lead product candidate?",
            "answer": "InMed's lead product candidate is INM-088, targeting ocular diseases."
        },
        {
            "question": "When was InMed Pharmaceuticals founded?",
            "answer": "InMed Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "TLRY"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "MRNA",
        "BMY"
    ]
}